Ten years ago, a consensus report on the optimization of tacrolimus was published in this
journal. In 2017, the Immunosuppressive Drugs Scientific Committee of the International …

The use of the calcineurin inhibitors cyclosporine and tacrolimus led to major advances in
the field of transplantation, with excellent short-term outcome. However, the chronic …

Tacrolimus is the mainstay immunosuppressant drug used after solid organ and
hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive and …

Abstract Tacrolimus (or FK506), a calcineurin inhibitor (CNI) introduced in field of
transplantation in the 1990s, is the cornerstone of most immunosuppressive regimens in …

The calcineurin inhibitors ciclosporin (cyclosporine) and tacrolimus are immunosuppressant
drugs used for the prevention of organ rejection following transplantation. Both agents are …

Tacrolimus (FK506) and cyclosporine (cyclosporin A, CsA) are cornerstone
immunosuppressive agents administered to solid organ transplant recipients to prevent and …

In 2007, a consortium of European experts on tacrolimus (TAC) met to discuss the most
recent advances in the drug/dose optimization of TAC taking into account specific clinical …

Background: Tacrolimus (Tac, or FK506), a calcineurin inhibitor (CNI), is the first-line
immunosuppressant which consists of the footstone as immunosuppressive regimens in …

The calcineurin inhibitor tacrolimus is the backbone of immunosuppressive drug therapy
after solid organ transplantation. Tacrolimus is effective in preventing acute rejection but has …

Tacrolimus (Tac) is widely used for the prevention of rejection after solid organ
transplantation. Finding the optimal balance between effective Tac concentrations and …